Keywords: Atherosclerosis, Cardiovascular Disease, Carotid Intima-Media Thickness, Endothelial Dysfunction, Longevity, Magnesium, Serum Magnesium, Vascular Calcification
Introduction
Cardiovascular disease (CVD) remains the foremost cause of premature mortality and disability-adjusted life years globally, with atherosclerosis underpinning the majority of acute coronary syndromes, strokes, and peripheral vascular events. The atherosclerotic process is characterized by a complex interplay of dyslipidemia, endothelial injury, chronic low-grade inflammation, and pathological mineralization of the vessel wall, culminating in arterial stiffening, luminal narrowing, and plaque instability [1].
Despite the dominance of statin therapy and lifestyle modification in cardiovascular prevention, a substantial residual risk persists, prompting investigation of complementary biological modulators. Among these, magnesium (Mg2+), the fourth most abundant cation in the human body and a cofactor in over 300 enzymatic reactions has attracted growing scientific attention. Magnesium governs critical vascular processes including ion channel regulation, smooth muscle tone, endothelial homeostasis, glucose-insulin signaling, and the suppression of inflammatory cascades [1,2].
Epidemiological evidence consistently links dietary magnesium inadequacy to heightened cardiovascular risk, while preclinical studies reveal that magnesium can not only inhibit vascular calcification but reverse the osteogenic transformation of VSMCs, a process central to the hardening of arterial plaques. Given that magnesium deficiency is among the most prevalent micronutrient insufficiencies in industrialized populations, its role as a modifiable determinant of atherosclerosis progression deserves closer clinical scrutiny [3,4].
This review synthesizes current molecular, preclinical, and clinical evidence examining magnesium’s capacity to modulate arterial plaque dynamics, with particular emphasis on its relevance to preventive cardiovascular and longevity medicine.
Pathophysiology of Atherosclerosis: A Brief Overview
Atherosclerosis initiates at sites of disturbed blood flow, where haemodynamic shear stress triggers endothelial activation and increased vascular permeability. Low-density lipoprotein (LDL) particles infiltrate the subendothelial space, undergo oxidative modification to form oxidized LDL (oxLDL), and stimulate the release of adhesion molecules including VCAM-1 and ICAM-1, facilitating monocyte recruitment and extravasation [14].
Monocytes differentiate into macrophages within the intima, avidly internalizing oxLDL via scavenger receptors (CD36, LOX-1, SR-A1) to become lipid-laden foam cells, the hallmark of the early atherosclerotic lesion. As the lesion progresses, vascular smooth muscle cells (VSMCs) migrate from the tunica media into the intima, proliferate, and undergo phenotypic switching away from a contractile toward a synthetic phenotype [14,17].
A critical and clinically underappreciated step is the osteogenic transdifferentiation of VSMCs, driven by signaling pathways including Wnt/beta-catenin and bone morphogenetic protein (BMP), with upregulation of the RUNX2/Cbfa-1 transcription factor. This transdifferentiation converts VSMCs into mineralizing cells that deposit hydroxyapatite within the plaque matrix, generating calcified lesions associated with plaque vulnerability and arterial stiffening. Concomitant inflammation, mediated by NF-kappaB activation, reactive oxygen species (ROS) generation, and NLRP3 inflammasome activity, perpetuates and amplifies the entire process [2,5].
Magnesium Deficiency and Cardiovascular Risk
Epidemiological surveys estimate that over 50% of adults in Western nations fail to meet recommended daily magnesium intakes (320-420 mg/day), placing a large proportion of the population in a state of chronic latent hypomagnesaemia. Serum magnesium levels below 0.75 mmol/L are associated with a significantly elevated risk of hypertension, metabolic syndrome, type 2 diabetes, atrial fibrillation, and coronary artery disease, conditions that collectively accelerate the atherogenic process [3].
A dose-response meta-analysis of 40 prospective cohort studies involving more than one million participants demonstrated a significant inverse association between dietary magnesium intake and the risk of cardiovascular events and all-cause mortality. For every 100 mg/day increment in dietary magnesium, the risk of CVD was reduced by approximately 7%. A separate meta-analysis of nine studies encompassing 77,821 coronary heart disease cases revealed that higher magnesium concentrations in drinking water were inversely associated with coronary heart disease mortality (relative risk 0.89; 95% CI 0.79-0.99) [15,16].
Beyond dietary surveys, circulating magnesium levels serve as a biological marker of vascular risk. Low serum magnesium is independently associated with hypertension, coronary artery calcification, subclinical atherosclerosis, and cardiac mortality, with each 0.1 mmol/L reduction in serum magnesium conferring a measurable increment in cardiovascular event risk [1,19].
Molecular Mechanisms of Magnesium in Vascular Calcification and Plaque Modulation
Inhibition of Hydroxypatite Crystal Formation
The fundamental driver of arterial mineralization is the precipitation of calcium phosphate as hydroxyapatite (Ca10(PO4)6(OH)2) within the vascular extracellular matrix. In vitro studies demonstrate that magnesium ions competitively inhibit calcium incorporation into the hydroxyapatite crystal lattice, reducing calcium and phosphate content of extracellular crystals by 68% and 41%, respectively, under physiological magnesium concentrations. This physicochemical inhibition constitutes the most direct anti-calcification mechanism of magnesium [6].
Ter Braake et al. confirmed in a comprehensive review that increasing extracellular magnesium concentration inhibits hydroxyapatite nucleation and growth through both passive physicochemical interference and active cellular modulation. Dietary magnesium supplementation in animal models of chronic kidney disease, a paradigm of accelerated vascular calcification, significantly attenuated aortic and peripheral calcification scores compared to controls, validating the in vitro observations in a clinically relevant in vivo setting [4,8].
Reversal of Osteogenic Transdifferentiation via Wnt/beta-Catenin Inhibition
Perhaps the most clinically compelling finding is magnesium’s ability not merely to prevent, but to reverse established vascular calcification. When VSMCs are exposed to elevated phosphate, a pro-calcification stimulus, they undergo osteogenic transdifferentiation characterized by upregulation of RUNX2/Cbfa-1 and osterix transcription factors. Zhu et al. demonstrated that moderately elevated extracellular magnesium (1.4 mM) significantly reduced VSMC calcification induced by high-phosphate conditions and, critically, reversed pre-established calcification in VSMCs already undergoing osteogenic transition [5].
The intracellular mechanism involves suppression of the Wnt/beta-catenin signaling pathway, a master regulator of osteogenic differentiation. Silencing of the magnesium transporter TRPM7 via siRNA abrogated the protective effects of magnesium, confirming that cellular magnesium uptake through specific transporter channels is required for anti-calcification activity. This establishes magnesium as an active biological regulator of vascular mineralization, not merely a passive ionic competitor [5].
Upregulation of Endogenous Calcification Inhibitors: MGP and OPG
Magnesium modulates the expression of two critical endogenous inhibitors of vascular calcification: matrix Gla protein (MGP) and osteoprotegerin (OPG). MGP, a vitamin K-dependent protein secreted by VSMCs, is considered the most potent local inhibitor of vascular calcification; MGP-deficient mice develop fatal arterial calcification within weeks of birth. Magnesium exposure upregulates MGP expression in VSMCs concurrently with reduction in osteogenic transcription factor activity, providing a dual mechanism of calcification suppression [5,7].
OPG, a decoy receptor for RANK ligand, inhibits osteoclast-like activity within the vascular wall. Its upregulation by magnesium further shifts the intimal microenvironment away from mineralization and toward extracellular matrix preservation. Together, these mechanisms support the capacity of adequate magnesium levels to retard and partially reverse the calcification phase of plaque maturation [4,7].
Anti-Atherogenic Properties of Magnesium
Endothelial Protection and Nitric Oxide Signaling
Endothelial dysfunction is the initiating event in atherogenesis, characterized by impaired nitric oxide (NO) bioavailability, increased oxidative stress, and a pro-inflammatory, pro-adhesive surface phenotype. Magnesium deficiency reduces endothelial nitric oxide synthase (eNOS) activity, diminishes NO production, and promotes the expression of monocyte adhesion molecules, establishing conditions conducive to early plaque formation [3].
Conversely, adequate intracellular magnesium maintains the balance between vasodilatory and vasoconstrictive mediators by acting as a physiological antagonist at L-type voltage-gated calcium channels. This calcium-magnesium antagonism reduces smooth muscle contractility and vasospasm, preserving endothelial structural integrity. Magnesium also attenuates inducible nitric oxide synthase (iNOS) over-activation, a source of reactive nitrogen species that damages the endothelial glycocalyx and amplifies NF-kappaB-driven inflammatory signaling [1-3].
Anti-Inflammatory and Antioxidant Effects
Magnesium deficiency activates NF-kappaB, NADPH oxidase, and the NLRP3 inflammasome, creating a pro-inflammatory milieu that promotes foam cell retention, extracellular matrix degradation, and plaque vulnerability. Elevated intracellular ROS under hypomagnesaemic conditions trigger lipid peroxidation of LDL particles, generating oxLDL, the principal ligand for scavenger receptor-mediated foam cell formation [2].
Clinical studies demonstrate that magnesium supplementation in coronary artery disease patients significantly reduces circulating markers of oxidative stress and inflammation, including oxLDL receptor expression in vascular endothelial cells and plasma lipid peroxidation products. Furthermore, magnesium deficiency promotes lipid accumulation in endothelial cells through upregulation of oxidative stress pathways involving EDF-1 and suppression of PPARgamma, a nuclear receptor with established anti-atherogenic properties [18,20].
Attenuation of Foam Cell Formation and VSMC Pyroptosis
oxLDL-stimulated VSMCs undergo cholesterol ester accumulation and transdifferentiation into VSMC-derived foam cells, a process increasingly recognized as parallel to macrophage foam cell formation in plaque pathobiology. Li et al. demonstrated that magnesium chloride (MgCl2) pretreatment dose-dependently attenuated ox-LDL-induced pyroptosis in VSMC-derived foam cells by downregulating the TLR4/NF-kappaB signaling axis and reducing NLRP3 inflammasome activation [17].
Pyroptotic cell death releases pro-inflammatory cytokines (IL-1beta, IL-18) that destabilise the fibrous cap and promote plaque rupture, the proximate cause of acute myocardial infarction. Magnesium’s capacity to suppress VSMC pyroptosis thus represents an important mechanism for maintaining plaque stability and reducing acute event risk, independent of effects on plaque volume [2,17].
Clinical and Epidemiological Evidence
Serum Magnesium and Carotid Intima-Media Thickness
Carotid intima-media thickness (cIMT) is a validated surrogate marker of subclinical atherosclerosis and a predictor of future major adverse cardiovascular events. The CORDIOPREV study, a prospective cohort of 939 patients with established coronary heart disease, demonstrated a strong inverse association between serum magnesium and cIMT, with each 1 mg/dL increment in serum magnesium associated with a 0.111 mm reduction in cIMT (p < 0.001). This association persisted after adjustment for confounders including glucose metabolism, lipid profiles, and renal function, suggesting a direct vascular effect independent of cardiometabolic risk factor modification [9].
A community-based cross-sectional study of 2,837 Chinese participants aged 40-75 years similarly found that both serum and urinary magnesium concentrations were inversely associated with common carotid artery IMT after multivariable adjustment. Furthermore, in hemodialysis patients, a population with accelerated vascular calcification those with serum magnesium >= 2.3 mg/dL had significantly lower mean cIMT (0.93 +/- 0.22 mm vs. 1.03 +/- 0.22 mm, p < 0.05) compared to patients with lower magnesium levels [10,11].
Coronary Artery Calcification
Serum magnesium has been inversely associated with coronary artery calcification (CAC) score, a computed tomography-derived quantitative measure of plaque calcium burden in the Genetics of Atherosclerotic Disease (GEA) study, a Mexican population cohort with high prevalence of cardiometabolic disease. After adjustment for established cardiovascular risk factors, each standard deviation increment in serum magnesium was associated with a significant reduction in CAC score, reinforcing the proposition that systemic magnesium status directly and independently influences the calcification component of atherosclerotic plaque progression [11].
Randomized Controlled Trials on Arterial Stiffness
Arterial stiffness, quantified by carotid-to-femoral pulse wave velocity (PWV), the gold-standard method integrates the structural consequences of both calcification and collagen cross-linking within the arterial wall, and is a powerful independent predictor of cardiovascular events. A randomized, double-blind, placebo-controlled trial by Joris et al. demonstrated that 350 mg/day of magnesium supplementation for 24 weeks significantly reduced PWV by 1.0 m/s in overweight and obese adults. Longitudinal epidemiological modelling estimates that a 1 m/s PWV reduction corresponds to a 14% decrease in major cardiovascular event risk, underscoring the potential clinical magnitude of this finding [12].
A double-blind clinical trial in coronary artery disease patients receiving intravenous magnesium sulfate demonstrated significant improvements in oxLDL levels, endothelial-dependent vasodilation, and inflammatory biomarkers relative to placebo. Conversely, a more recent trial of 450 mg/day magnesium citrate did not find statistically significant changes in arterial stiffness at 24 weeks, suggesting that dose, supplemental form, and baseline magnesium status critically influence clinical outcomes. These discrepancies underscore the need for adequately powered trials stratified by baseline intracellular magnesium [13,18].
Magnesium in Longevity and Metabolic Disease Prevention
The field of longevity medicine operates on the premise that subclinical arterial aging, characterized by cumulative plaque burden, arterial stiffening, and endothelial senescence, precedes and predicts clinical cardiovascular events by decades. Within this framework, magnesium emerges as an accessible and physiologically plausible modulator of vascular biological age, acting simultaneously on multiple hallmarks of vascular aging [1].
Magnesium’s involvement extends beyond direct vascular effects: it governs insulin receptor substrate phosphorylation, mitochondrial ATP synthesis, DNA repair fidelity, and redox homeostasis, processes directly linked to metabolic disease and cellular aging. Hypomagnesaemia is mechanistically implicated in insulin resistance, the cornerstone of metabolic syndrome and a major driver of atherogenic dyslipidaemia, endothelial inflammation, and pro-coagulant states that collectively accelerate atherosclerosis progression [20,31].
From a preventive standpoint, the widespread prevalence of subclinical magnesium deficiency often invisible to routine serum testing due to tight homeostatic buffering from bone stores, represents a population-level vascular risk factor amenable to dietary and supplemental intervention. Magnesium-rich dietary patterns (dark leafy vegetables, nuts, seeds, legumes, whole grains) align closely with dietary approaches associated with longevity and reduced cardiometabolic risk, suggesting that magnesium may partly mediate the vascular benefits of these dietary patterns [1,19].
Future Research Directions
Despite mechanistic plausibility and encouraging preliminary clinical data, several gaps constrain definitive conclusions regarding magnesium’s plaque-modifying capacity. First, randomized controlled trials specifically powered to assess plaque regression, measured by coronary CT angiography or advanced carotid plaque characterization are entirely lacking. Second, optimal serum or intracellular magnesium targets for vascular protection remain undefined, complicated by the insensitivity of serum magnesium as a surrogate for whole-body magnesium stores, with red blood cell or intralymphocytic magnesium potentially serving as more accurate biomarkers [4].
Third, the influence of magnesium bioavailability across different supplemental forms such as magnesium citrate, glycinate, malate, threonate, and oxide on vascular endpoints requires systematic comparative investigation. Fourth, interactions with key co-factors, notably vitamin K2 (required for MGP gamma-carboxylation and activation), vitamin D (which modulates intestinal magnesium absorption), and calcium must be considered in the design of multi-modal interventions targeting vascular calcification [4,7].
Finally, the role of gut microbiome composition in determining magnesium absorption efficiency and the bidirectional relationship between microbiome diversity, systemic inflammation, and atherosclerosis progression represents an emerging frontier with implications for personalized longevity medicine. Large-scale Mendelian randomization studies leveraging genetic variants influencing magnesium homeostasis may provide the causal inference needed to guide future clinical trials
Conclusion
Magnesium is no longer appropriately characterized as a passive electrolyte. Converging molecular, preclinical, and clinical evidence positions Mg2+ as an active regulator of arterial plaque biology through multiple complementary mechanisms: physicochemical inhibition of hydroxyapatite crystal formation; reversal of VSMC osteogenic transdifferentiation via Wnt/beta-catenin suppression; upregulation of the endogenous calcification inhibitors MGP and OPG; protection of endothelial nitric oxide signaling; attenuation of NF-kappaB-driven inflammation and oxidative stress; and reduction of foam cell pyroptosis [4-7].
Epidemiological data consistently demonstrate that higher magnesium status correlates with lower cIMT, reduced coronary artery calcification scores, and decreased cardiovascular mortality, while randomized trials support clinically meaningful improvements in arterial stiffness with supplemental magnesium in at-risk populations [9-12,15,16].
For clinicians and researchers in longevity and preventive cardiovascular medicine, these findings advocate for systematic assessment of magnesium status, beyond standard serum measurements and consideration of optimized magnesium intake as part of a comprehensive anti-atherogenic strategy. While definitive plaque regression trials remain a critical unmet need, the available evidence provides a compelling scientific rationale for repositioning magnesium at the centre of vascular longevity therapeutics.
Reference
1. Severino P, D’Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. The role of dietary magnesium in cardiovascular disease. Nutrients. 2024;16(23):4223.
2. Barbagallo M, Veronese N, Dominguez LJ. Magnesium, oxidative stress, inflammation, and cardiovascular disease. Antioxidants (Basel). 2020;9(10):907.
3. Severino P, D’Amato A, Netti L, Pucci M, De Marchis M, Colletti M, et al. Prevention of cardiovascular disease: screening for magnesium deficiency. Cardiol Res Pract. 2019;2019:4874921.
4. Ter Braake AD, Shanahan CM, de Baaij JHF. Magnesium counteracts vascular calcification: passive interference or active modulation? Arterioscler Thromb Vasc Biol. 2017;37(8):1431–45.
5. Zhu Q, Kao L, Azimov R, Abuladze N, Newman D, Bhatt D, et al. Magnesium inhibits Wnt/beta-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One. 2014;9(2):e89525.
6. Louvet L, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep. 2018;8:2069.
7. Mehansho H, Hammerstone JL. Prevention of vascular calcification by magnesium and selected polyphenols. Adv Prev Med. 2021;2021:6686597.
8. Diaz-Tocados JM, Peralta-Ramirez A, Rodriguez-Ortiz ME, et al. Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease. Nephrol Dial Transplant. 2022;37(6):1049–59.
9. Hernandez JL, Olmos JM, Pariente E, Nan D, Martinez J, Valero C, et al. Serum magnesium is associated with carotid atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). Sci Rep. 2019;9(1):8013.
10. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, et al. Association of magnesium in serum and urine with carotid intima-media thickness and serum lipids in middle-aged and elderly Chinese: a community-based cross-sectional study. Eur J Nutr. 2016;55(1):219–29.
11. Rodriguez-Ramirez M, Simental-Mendia LE, Gonzalez-Ortiz M, et al. Serum magnesium is inversely associated with coronary artery calcification in the Genetics of Atherosclerotic Disease (GEA) study. Nutr Metab Cardiovasc Dis. 2016;26(3):214–21.
12. Joris PJ, Plat J, Bakker SJ, Mensink RP. Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial. Am J Clin Nutr. 2016;103(5):1260–6.
13. Verburg FA, Collet TH, Baumgartner C, Muendlein A, Vonbank A, Heinzle C, et al. Effects of magnesium citrate, magnesium oxide, and magnesium sulfate supplementation on arterial stiffness: a randomized, double-blind, placebo-controlled intervention trial. J Am Heart Assoc. 2022;11(10):e021783.
14. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The atherosclerosis concept in the 21st century: clinical implications. Dis Markers. 2020;2020:8438802.
15. Del Gobbo LC, Xun P, Djousse L, He K, et al. Magnesium levels in drinking water and coronary heart disease mortality risk: a meta-analysis. Curr Hypertens Rep. 2016;18(1):12.
16. Fang X, Wang K, Han D, He X, Wei J, Zhao L, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med. 2016;14:210.
17. Li Y, Ding S, Wang X, Guo X, Wang H. MgCl2 attenuates ox-LDL-induced vascular smooth muscle-derived foam cells pyroptosis by downregulating the TLR4/NF-kappaB signaling pathway. Biol Trace Elem Res. 2023;201(7):3227–37.
18. Guerrero-Romero F, Rodriguez-Moran M, Hernandez-Ronquillo G, Gomez-Diaz R, Wacher N, Garay-Sevilla ME, et al. Magnesium sulfate improves some risk factors for atherosclerosis in patients suffering from one or two coronary artery diseases: a double-blind clinical trial study. Clin Pharmacol Adv Appl. 2020;12:119–27.
19. Rosique-Esteban N, Guasch-Ferre M, Hernandez-Alonso P, Salas-Salvado J. Dietary magnesium and cardiovascular disease: a review with emphasis in epidemiological studies. Nutrients. 2018;10(2):168.
20. Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014;22(4):182–92.